Document is current
Any future updates will be listed below
-
Authors
Morgenstern, Travis J.
Nirwan, Neha
Hernández-Ochoa, Erick O.
Bibollet, Hugo https://orcid.org/0000-0001-7020-586X
Choudhury, Papiya
Laloudakis, Yianni D.
Ben Johny, Manu https://orcid.org/0000-0002-5645-0815
Bannister, Roger A.
Schneider, Martin F.
Minor, Daniel L. Jr https://orcid.org/0000-0002-5998-4214
Colecraft, Henry M. https://orcid.org/0000-0002-2340-8899
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (F31 DK118866)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR075726)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01 NS103777)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL080050, RO1 HL122421, RO1 HL121253)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | National Institutes of Health (S10 RR027050, P30 CA013696)
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 10 June 2022
Accepted: 15 November 2022
First Online: 9 December 2022
Competing interests
: T.J.M. and H.M.C. have filed a patent application through Columbia University based on this work. T.J.M. and H.M.C., 2019. Composition and methods for genetically-encoded high voltage-activated calcium channel blockers using engineered ubiquitin ligases (U.S. Application Serial No. 62/830,142). The remaining authors declare no competing interests.
